| Literature DB >> 31695253 |
Sonal Krishan1, Radha K Dhiman2, Navin Kalra3, Raju Sharma4, Sanjay S Baijal5, Anil Arora6, Ajay Gulati3, Anu Eapan7, Ashish Verma8, Shyam Keshava7, Amar Mukund9, S Deva4, Ravi Chaudhary1, Karthick Ganesan10, Sunil Taneja2, Ujjwal Gorsi3, Shivanand Gamanagatti4, Kumble S Madhusudan4, Pankaj Puri6, Shallini Govil11, Manav Wadhavan12, Sanjiv Saigal13, Ashish Kumar6, Shallini Thapar14, Ajay Duseja2, Neeraj Saraf13, Anubhav Khandelwal15, Sumit Mukhopadyay16, Ajay Gulati3, Nitin Shetty16, Nipun Verma2.
Abstract
Hepatocellular carcinoma (HCC) is the 6th most common cancer and the second most common cause of cancer-related mortality worldwide. There are currently no universally accepted practice guidelines for the diagnosis of HCC on imaging owing to the regional differences in epidemiology, target population, diagnostic imaging modalities, and staging and transplant eligibility. Currently available regional and national guidelines include those from the American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the Liver (EASL), the Asian Pacific Association for the Study of the Liver, the Japan Society of Hepatology, the Korean Liver Cancer Study Group, Hong Kong, and the National Comprehensive Cancer Network in the United States. India with its large population and a diverse health infrastructure faces challenges unique to its population in diagnosing HCC. Recently, American Association have introduced a Liver Imaging Reporting and Data System (LIRADS, version 2017, 2018) as an attempt to standardize the acquisition, interpretation, and reporting of liver lesions on imaging and hence improve the coherence between radiologists and clinicians and provide guidance for the management of HCC. The aim of the present consensus was to find a common ground in reporting and interpreting liver lesions pertaining to HCC on imaging keeping LIRADSv2018 in mind.Entities:
Keywords: APHE; CT; HCC; LIRADS; Liver Imaging Reporting and Data System; MR; MRCP; arterial phase hyperenhancement; computed tomography; hepatocellular carcinoma; magnetic resonance; magnetic resonance cholangiopancreatography
Year: 2019 PMID: 31695253 PMCID: PMC6823668 DOI: 10.1016/j.jceh.2019.07.005
Source DB: PubMed Journal: J Clin Exp Hepatol ISSN: 0973-6883